Novel amides useful for treating pain

Abstract

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R 6 , R 7 and R 8 are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.

1 . A compound of formula (VII) 
       
         
           
           
               
               
           
         
       
       wherein
 X 1  is N or CR 1 ; 
 X 5  is N or CR 5 ; 
 X 6  is a bond or CR 6 ; 
 X 7  is N or CR 7 ; 
 X 8  is N or CR 8 ; 
 X 9  is N or CR 9 ; 
 R 1 , R 5 , and R 9  are independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl and heterocycle; 
 R 7  is hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkoxycarbonylalkyl, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkyl, aryloxy, arylthio, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, cycloalkylthio, haloalkoxy, haloalkyl, haloalkylsulfonyl, haloalkylthio, halogen, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylthio, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, R C R D N—, (R A R B N)carbonyl-, (R A R B N)sulfonyl-; or R A S(O) 2 —; 
 R 6  and R 8  are independently hydrogen, lower alkenyl, lower alkoxy, lower alkyl, lower alkylthio, lower alkynyl, lower haloalkoxy, lower haloalkyl, lower haloalkylthio, halogen, hydroxy, mercapto, or R A R B N—; 
 R A  and R B  are independently alkyl, hydrogen, haloalkyl, or heterocycle; and 
 R C  and R D  are independently hydrogen, alkenyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkynyl, or (NR A R B )carbonyl. 
 
     
     
         2 . A compound according to  claim 1 , wherein
 X 1  is CR 1 ;   X 5  is CR 5 ;   X 6  is CR 6 ;   X 7  is CR 7 ;   X 8  is CR 8 ;   X 9  is N or CR 9 ;   R 7  and R 8  are independently selected from the group consisting of hydrogen, alkyl, and halogen.   
     
     
         3 . A compound according to  claim 2  that is 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (5-fluoro-pyridin-2-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (5-chloro-pyridin-2-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (5-bromo-pyridin-2-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (5-iodo-pyridin-2-yl)-amide; or 
       3′-Trifluoromethyl-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (5-iodo-pyridin-2-yl)-amide. 
     
     
         4 . The compound according to  claim 1 , wherein
 X 1  is CR 1 ;   X 5  is CR 5 ;   X 6  is CR 6 ;   X 7  is CR 7 ;   X 8  is N;   X 9  is CR 9 ;   R 5 , R 6 , R 9  and R 1 , are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, and halogen;   R 7  is hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkoxycarbonylalkyl, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkyl, aryloxy, arylthio, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, cycloalkylthio, haloalkoxy, haloalkyl, haloalkylsulfonyl, haloalkylthio, halogen, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylthio, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, R C R D N—, (R A R B N)carbonyl-, (R A R B N)sulfonyl-; or R A S(O) 2 —;   R A  and R B  are independently alkyl, hydrogen, haloalkyl, or heterocycle; and   R C  and R D  are independently hydrogen, alkenyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkynyl, or (NR A R B )carbonyl-.   
     
     
         5 . A compound according to  claim 4  that is 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (6-trifluoromethyl-pyridin-3-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (6-chloro-pyridin-3-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-amide; 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (6-azepan-1-yl-pyridin-3-yl)-amide; or 
       3′-Trifluoromethyl-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (6-trifluoromethyl-pyridin-3-yl)-amide. 
     
     
         6 . The compound according to  claim 1 , wherein 
       wherein
 X 1  is CR 1 ; 
 X 5  is CR 5 ; 
 X 6  is a bond; 
 X 7  is N; 
 X 8  is N; 
 X 9  is CR 9 ; 
 R 1 , R 9  and R 5 , are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, and halogen. 
 
     
     
         7 . The compound according to  claim 6  that is 
       3′-Chloro-3,6-dihydro-2H-[1,2′]bipyridinyl-4-carboxylic acid (1-tert-butyl-1H-pyrazol-4-yl)-amide. 
     
     
         8 . A compound according to  claim 1   X 1  is N;   X 5  is CR 5 ;   X 6  is CR 6 ;   X 7  is CR 7 ;   X 8  is N;   X 9  is CR 9 ;   R 6 , R 7 , R 9  and R 5 , are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, and halogen.   
     
     
         9 . A compound according to  claim 8  that is 
       1-pyrimidin-2-yl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid (6-trifluoromethyl-pyridin-3-yl)-amide 
     
     
         10 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (VII) according to  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A method of treating pain in a mammal, comprising administering a therapeutically effective amount of a compound of formula (VII) according to  claim 1  or a pharmaceutically acceptable salt thereof.